(Q50745427)

English

Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis.

scientific article published in April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

0 references

1 reference

based on heuristic

inferred from title

author name string

T Bito

1

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

R Nishikawa

2

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

M Hatakeyama

3

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

A Kikusawa

4

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

H Kanki

5

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

H Nagai

6

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

Y Sarayama

7

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

T Ikeda

8

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

H Yoshizaki

9

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

H Seto

10

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

A Adachi

11

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

T Horikawa

12

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

M Oka

13

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

C Nishigori

14

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

language of work or name

0 references

publication date

1 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

British Journal of Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

170

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

4

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

922-929

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12791

21 January 2018

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12791

21 January 2018

Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12791

21 January 2018

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12791

21 January 2018

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12791

21 January 2018

Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12791

21 January 2018

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12791

21 January 2018

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12791

21 January 2018

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12791

21 January 2018

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12791

21 January 2018

Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12791

21 January 2018

Identifiers

10.1111/BJD.12791

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 March 2018

http://europepmc.org/abstract/MED/24329764

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50745427&oldid=1250872561"